Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20;12(10):1745.
doi: 10.3390/jpm12101745.

Advanced Bladder Cancer: Changing the Treatment Landscape

Vladimir Bilim  1   2 , Hiroo Kuroki  1   3 , Yuko Shirono  1 , Masaki Murata  1 , Kaede Hiruma  1 , Yoshihiko Tomita  1
Affiliations
Review

Advanced Bladder Cancer: Changing the Treatment Landscape

Vladimir Bilim et al. J Pers Med. .

Abstract

Bladder cancer is the 10th most common cancer type in the world. There were more than 573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer death with an estimated more than 212,000 deaths worldwide. Low-grade non-muscle-invasive bladder cancer (NMIBC) is usually successfully managed with transurethral resection (TUR) and overall survival for NMIBC reaches 90% according to some reports. However, long-term survival for muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer remains low. Treatment options for bladder cancer have undergone a rapid change in recent years. Immune checkpoint inhibitors (ICI), targeted therapies, and antibody-drug conjugates are available now. As bladder cancer is genetically heterogeneous, the optimization of patient selection to identify those most likely to benefit from a specific therapy is an urgent issue in the treatment of patients with bladder cancer.

Keywords: bladder cancer; urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of BC clinical trials and FDA approval.
See this image and copyright information in PMC

References

    1. WCRF World Cancer Research Fund International. [(accessed on 8 July 2022)]. Available online: https://www.wcrf.org/diet-activity-and-cancer/cancer-types/bladder-cancer/
    1. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet. 2009;374:239–249. doi: 10.1016/S0140-6736(09)60491-8. - DOI - PubMed
    1. Mazonakis M., Lyraraki E., Tolia M., Damilakis J. Risk for second bladder and rectal malignancies from cervical cancer irradiation. J. Appl. Clin. Med. Phys. 2021;22:103–109. doi: 10.1002/acm2.13274. - DOI - PMC - PubMed
    1. Zhang H., Yu A., Baran A., Messing E. Risk of second cancer among young prostate cancer survivors. Radiat Oncol. J. 2021;39:91. doi: 10.3857/roj.2020.00857. - DOI - PMC - PubMed
    1. Siefker-Radtke A. Urachal adenocarcinoma: A clinician’s guide for treatment. Semin Oncol. 2012;39:619–624. doi: 10.1053/j.seminoncol.2012.08.011. - DOI - PubMed